Table 1 (abstract A.57). Change from baseline in monthly average migraine days during 12-weeks of double-blind treatment by sex and age group^a

Males

(n = 46)

(n = 45)

(n = 47)

 LSM (SE) change

−0.4 (0.74)

−4.6 (0.78)

−4.2 (0.73)

 LSMD (SE) vs placebo

–

−4.2 (0.91)^b

− 3.8 (0.87)^b

Females

(n = 232)

(n = 238)

(n = 229)

 LSM (SE) change

−0.6 (0.35)

−3.9 (0.34)

−3.6 (0.35)

 LSMD (SE) vs placebo

–

−3.3 (0.39)^b

− 3.0 (0.39)^b

Age 18–45 years

(n = 120)

(n = 128)

(n = 125)

 LSM (SE) change

−0.8 (0.47)

−4.6 (0.49)

−4.1 (0.48)

 LSMD (SE) vs placebo

–

−3.8 (0.51)^b

− 3.2 (0.51)^b

Age > 45 years

(n = 158)

(n = 155)

(n = 151)

 LSM (SE) change

−0.4 (0.48)

−3.8 (0.47)

−3.6 (0.49)

 LSMD (SE) vs placebo

–

−3.4 (0.50)^b

− 3.2 (0.51)^b